DE69934227D1 - Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide - Google Patents
Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotideInfo
- Publication number
- DE69934227D1 DE69934227D1 DE69934227T DE69934227T DE69934227D1 DE 69934227 D1 DE69934227 D1 DE 69934227D1 DE 69934227 T DE69934227 T DE 69934227T DE 69934227 T DE69934227 T DE 69934227T DE 69934227 D1 DE69934227 D1 DE 69934227D1
- Authority
- DE
- Germany
- Prior art keywords
- relates
- antisense oligonucleotides
- arabinosis
- analogs
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 239000002214 arabinonucleotide Substances 0.000 abstract 2
- 108020004394 Complementary RNA Proteins 0.000 abstract 1
- 108020000999 Viral RNA Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract 1
- -1 arabinose sugars Chemical class 0.000 abstract 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000003184 complementary RNA Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2241361 | 1998-06-19 | ||
| CA2241361 | 1998-06-19 | ||
| PCT/CA1999/000571 WO1999067378A1 (en) | 1998-06-19 | 1999-06-17 | ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β-ARABINOFURANOSE AND ITS ANALOGUES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69934227D1 true DE69934227D1 (de) | 2007-01-11 |
| DE69934227T2 DE69934227T2 (de) | 2007-10-04 |
Family
ID=4162575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69934227T Expired - Lifetime DE69934227T2 (de) | 1998-06-19 | 1999-06-17 | Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090105467A1 (de) |
| EP (1) | EP1088066B1 (de) |
| AT (1) | ATE346918T1 (de) |
| AU (1) | AU4595399A (de) |
| DE (1) | DE69934227T2 (de) |
| WO (1) | WO1999067378A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001085751A1 (en) * | 2000-05-09 | 2001-11-15 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
| AU2001289448B8 (en) * | 2000-09-06 | 2006-08-10 | Mcgill University | Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| CA2451738C (en) | 2001-07-06 | 2013-09-17 | Topigen Pharmaceutique Inc. | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| US20050043256A1 (en) | 2001-07-30 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
| US7132529B2 (en) * | 2001-07-30 | 2006-11-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
| NZ534396A (en) * | 2002-02-01 | 2006-11-30 | Univ Mcgill | Oligonucleotides comprising alternating segments of sugar-modified nucleosides and 2'-deoxynucleosides and uses thereof |
| US7381820B2 (en) | 2003-10-24 | 2008-06-03 | Yamasa Corporation | α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside |
| WO2006045202A1 (en) | 2004-10-29 | 2006-05-04 | Topigen Pharmaceuticals Inc. | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
| US20090324587A1 (en) | 2005-12-01 | 2009-12-31 | Neal Clifford Goodwin | Cancer Therapies and Pharmaceutical Compositions Used Therein |
| KR20090035662A (ko) | 2006-05-19 | 2009-04-10 | 토피겐 파마슈티컬스 인코포레이티드 | 포스포디에스테라아제의 발현에 영향을 미치는 올리고누클레오티드 |
| KR20110017881A (ko) | 2008-05-15 | 2011-02-22 | 토피겐 파마슈티컬스 인코포레이티드 | 감염 및 신생세포 증식 치료용 올리고뉴클레오티드 |
| JP2013520395A (ja) | 2009-02-22 | 2013-06-06 | ケムジーンズ コーポレーション | 治療、診断、ｇ‐テトラド形成オリゴヌクレオシド及びアプタマーといった生物学的応用のための新規修飾を取り入れたアラ‐２’‐ｏ‐メチル‐ヌクレオシド、当該ホスホラミダイト及びオリゴヌクレオチドの合成 |
| EP2638163B1 (de) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-assoziierte nicht-kodierende rnas |
| SI2739311T1 (en) | 2011-08-04 | 2018-07-31 | Amgen Inc. | Method for the treatment of bone defect defects |
| EP3533873A1 (de) | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimere oligonukleotidverbindungen |
| EP3712168A3 (de) | 2011-12-28 | 2020-10-14 | Amgen Inc. | Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern |
| HK1208700A1 (en) | 2012-05-16 | 2016-03-11 | Rana Therapeutics Inc. | Compositions and methods for modulating smn gene family expression |
| DK2850189T3 (en) | 2012-05-16 | 2019-02-25 | Translate Bio Ma Inc | COMPOSITIONS AND PROCEDURES FOR MODULATING GENEPRESSION |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| HK1214632A1 (zh) | 2012-11-05 | 2016-07-29 | Pronai Therapeutics, Inc. | 通過調節bcl2表達利用生物標誌物治療癌症的方法 |
| US10301624B2 (en) | 2014-06-25 | 2019-05-28 | The General Hospital Corporation | Targeting human satellite II (HSATII) |
| DE102014221734A1 (de) * | 2014-10-24 | 2016-04-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Messvorrichtung und System zur Schmelzkurvenanalyse eines DNA Microarrays, sowie Verwendung eines Fluoreszenzdetektorarrays zur Analyse |
| EP3481430A4 (de) | 2016-07-11 | 2020-04-01 | Translate Bio Ma, Inc. | Nukleinsäurekonjugate und verwendungen davon |
| WO2019025324A1 (en) | 2017-08-03 | 2019-02-07 | Karl-Franzens-Universität Graz | ANALOGUES OF PHOSPHOLIPIDS |
| US12178855B2 (en) | 2018-01-10 | 2024-12-31 | Translate Bio Ma, Inc. | Compositions and methods for facilitating delivery of synthetic nucleic acids to cells |
| WO2019183005A1 (en) | 2018-03-19 | 2019-09-26 | The Trustees Of The University Of Pennsylvania | 2'f-ana-let7 mediated utrophin upregulation for dmd therapy |
| JP2022502062A (ja) * | 2018-09-26 | 2022-01-11 | オーム ライフテック インコーポレイテッド | ２’ｆａｎａ修飾ｆｏｘｐ３アンチセンスオリゴヌクレオチドおよびその使用方法 |
| CN113453694A (zh) | 2019-01-22 | 2021-09-28 | 科罗生物公司 | Rna编辑的寡核苷酸及其用途 |
| WO2021142245A1 (en) | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990003370A1 (en) * | 1988-09-28 | 1990-04-05 | Microprobe Corporation | DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE |
| AU3222793A (en) * | 1991-11-26 | 1993-06-28 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
| US5795726A (en) * | 1996-11-12 | 1998-08-18 | Millennium Pharmaceuticals, Inc. | Methods for identifying compounds useful in treating type II diabetes |
| US5739119A (en) * | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| AU2001289448B8 (en) * | 2000-09-06 | 2006-08-10 | Mcgill University | Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| NZ534396A (en) * | 2002-02-01 | 2006-11-30 | Univ Mcgill | Oligonucleotides comprising alternating segments of sugar-modified nucleosides and 2'-deoxynucleosides and uses thereof |
-
1999
- 1999-06-17 AU AU45953/99A patent/AU4595399A/en not_active Abandoned
- 1999-06-17 DE DE69934227T patent/DE69934227T2/de not_active Expired - Lifetime
- 1999-06-17 EP EP99928945A patent/EP1088066B1/de not_active Expired - Lifetime
- 1999-06-17 AT AT99928945T patent/ATE346918T1/de not_active IP Right Cessation
- 1999-06-17 WO PCT/CA1999/000571 patent/WO1999067378A1/en active IP Right Grant
-
2007
- 2007-06-13 US US11/818,133 patent/US20090105467A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE346918T1 (de) | 2006-12-15 |
| DE69934227T2 (de) | 2007-10-04 |
| EP1088066A1 (de) | 2001-04-04 |
| WO1999067378A1 (en) | 1999-12-29 |
| AU4595399A (en) | 2000-01-10 |
| US20090105467A1 (en) | 2009-04-23 |
| EP1088066B1 (de) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
| ZA200304500B (en) | Method for inhibiting the expression of a target gene and medicament for treating a tumor disease. | |
| WO2003100017A3 (en) | Oligonucleotides having modified nucleoside units | |
| DK0731835T3 (da) | Antisense-oligonukleotider med tumorigenicitetshæmmende virkning | |
| AU5121399A (en) | Rna targeted 2'-modified oligonucleotides that are conformationally preorganized | |
| EP1163254A4 (de) | Antisense-therapie für trpm-2 | |
| NO991328D0 (no) | Trekomponents kimeriske antisense oligonukleotider | |
| DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| DE69734589D1 (de) | Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase | |
| ATE373671T1 (de) | Aminooxy-modifizierte oligonukleotide | |
| FI946201A0 (fi) | Itsestabiloidut oligonukleotidit terapeuttisina aineina | |
| ATE324440T1 (de) | Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen | |
| WO2001047944A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
| ATE293688T1 (de) | Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide | |
| HRP20100666T1 (hr) | ANTI MIOZINSKA Va siRNA I DEPIGMENTACIJA KOŽE | |
| DK1175489T3 (da) | Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider | |
| WO2000008140A3 (en) | Antisense oligonucleotides for the inhibition of vegf expression | |
| KR20040028771A (ko) | 비시엘-2 디엔에이 효소 | |
| WO2001048245A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| WO2001040521A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| CA2331333A1 (en) | Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues | |
| Yamakawa et al. | Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides | |
| WO2001051670A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| WO2001038586A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |